Euromedis Groupe SA (ALEMG) - Net Assets
Based on the latest financial reports, Euromedis Groupe SA (ALEMG) has net assets worth €16.61 Million EUR (≈ $19.42 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€39.78 Million ≈ $46.50 Million USD) and total liabilities (€23.17 Million ≈ $27.08 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Euromedis Groupe SA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €16.61 Million |
| % of Total Assets | 41.76% |
| Annual Growth Rate | -0.41% |
| 5-Year Change | -57.66% |
| 10-Year Change | -42.37% |
| Growth Volatility | 34.53 |
Euromedis Groupe SA - Net Assets Trend (2009–2024)
This chart illustrates how Euromedis Groupe SA's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Euromedis Groupe SA for the complete picture of this company's asset base.
Annual Net Assets for Euromedis Groupe SA (2009–2024)
The table below shows the annual net assets of Euromedis Groupe SA from 2009 to 2024. For live valuation and market cap data, see market value of Euromedis Groupe SA.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €16.48 Million ≈ $19.27 Million |
-27.04% |
| 2023-12-31 | €22.59 Million ≈ $26.41 Million |
-35.23% |
| 2022-12-31 | €34.88 Million ≈ $40.78 Million |
-15.42% |
| 2021-12-31 | €41.24 Million ≈ $48.21 Million |
+5.94% |
| 2020-12-31 | €38.93 Million ≈ $45.51 Million |
+120.49% |
| 2019-12-31 | €17.66 Million ≈ $20.64 Million |
-16.97% |
| 2018-12-31 | €21.26 Million ≈ $24.86 Million |
-23.50% |
| 2017-12-31 | €27.80 Million ≈ $32.50 Million |
-3.51% |
| 2016-12-31 | €28.81 Million ≈ $33.68 Million |
+0.72% |
| 2015-12-31 | €28.60 Million ≈ $33.44 Million |
+11.81% |
| 2014-12-31 | €25.58 Million ≈ $29.91 Million |
+9.24% |
| 2013-12-31 | €23.42 Million ≈ $27.38 Million |
+10.19% |
| 2012-12-31 | €21.25 Million ≈ $24.85 Million |
+5.34% |
| 2011-12-31 | €20.18 Million ≈ $23.59 Million |
+9.92% |
| 2010-12-31 | €18.35 Million ≈ $21.46 Million |
+4.73% |
| 2009-12-31 | €17.52 Million ≈ $20.49 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Euromedis Groupe SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 142.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €5.75 Million | 34.88% |
| Other Comprehensive Income | €3.20 Million | 19.44% |
| Other Components | €9.73 Million | 59.03% |
| Total Equity | €16.48 Million | 100.00% |
Euromedis Groupe SA Competitors by Market Cap
The table below lists competitors of Euromedis Groupe SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Millennium Pharmacon International
JK:SDPC
|
$14.11 Million |
|
Les Hôtels de Paris SA
PA:HDP
|
$14.11 Million |
|
RECYCLICO BATTERY METALS
F:ID4
|
$14.11 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
$14.11 Million |
|
Turbo Mech Bhd
KLSE:5167
|
$14.10 Million |
|
Bodycote PLC
LSE:BOY
|
$14.10 Million |
|
Iconic Minerals Ltd
V:ICM
|
$14.09 Million |
|
Marvel Gold Ltd
AU:MVL
|
$14.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Euromedis Groupe SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,591,392 to 16,483,808, a change of -6,107,584 (-27.0%).
- Net loss of 6,108,078 reduced equity.
- Other comprehensive income increased equity by 575,332.
- Other factors decreased equity by 574,838.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.11 Million | -37.06% |
| Other Comprehensive Income | €575.33K | +3.49% |
| Other Changes | €-574.84K | -3.49% |
| Total Change | €- | -27.04% |
Book Value vs Market Value Analysis
This analysis compares Euromedis Groupe SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.71x to 0.81x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €6.63 | €4.68 | x |
| 2010-12-31 | €7.28 | €4.68 | x |
| 2011-12-31 | €6.76 | €4.68 | x |
| 2012-12-31 | €7.12 | €4.68 | x |
| 2013-12-31 | €7.84 | €4.68 | x |
| 2014-12-31 | €8.56 | €4.68 | x |
| 2015-12-31 | €9.58 | €4.68 | x |
| 2016-12-31 | €9.64 | €4.68 | x |
| 2017-12-31 | €9.30 | €4.68 | x |
| 2018-12-31 | €7.17 | €4.68 | x |
| 2019-12-31 | €5.90 | €4.68 | x |
| 2020-12-31 | €10.90 | €4.68 | x |
| 2021-12-31 | €11.51 | €4.68 | x |
| 2022-12-31 | €11.87 | €4.68 | x |
| 2023-12-31 | €7.93 | €4.68 | x |
| 2024-12-31 | €5.79 | €4.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Euromedis Groupe SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.87%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 2.35x
- Recent ROE (-37.06%) is below the historical average (2.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -14.38% | -3.93% | 1.20x | 3.06x | €-4.28 Million |
| 2010 | 4.40% | 1.26% | 1.16x | 3.02x | €-1.03 Million |
| 2011 | -4.07% | -1.25% | 1.17x | 2.78x | €-2.85 Million |
| 2012 | 5.07% | 1.45% | 1.35x | 2.59x | €-1.05 Million |
| 2013 | 9.36% | 2.90% | 1.38x | 2.34x | €-149.00K |
| 2014 | 9.97% | 3.49% | 1.32x | 2.17x | €-7.60K |
| 2015 | 8.63% | 3.47% | 1.26x | 1.97x | €-391.10K |
| 2016 | 3.49% | 1.38% | 1.29x | 1.97x | €-1.88 Million |
| 2017 | -0.52% | -0.20% | 1.29x | 2.06x | €-2.93 Million |
| 2018 | -23.14% | -6.47% | 1.51x | 2.37x | €-7.05 Million |
| 2019 | -21.52% | -4.92% | 1.28x | 3.41x | €-5.56 Million |
| 2020 | 58.55% | 11.72% | 2.09x | 2.39x | €18.79 Million |
| 2021 | 5.50% | 2.02% | 1.54x | 1.77x | €-1.84 Million |
| 2022 | -17.16% | -10.99% | 0.91x | 1.73x | €-9.43 Million |
| 2023 | 58.03% | 35.03% | 0.81x | 2.05x | €10.85 Million |
| 2024 | -37.06% | -16.87% | 0.93x | 2.35x | €-7.76 Million |
Industry Comparison
This section compares Euromedis Groupe SA's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $17,768,372
- Average return on equity (ROE) among peers: 8.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Euromedis Groupe SA (ALEMG) | €16.61 Million | -14.38% | 1.39x | $14.10 Million |
| Bastide Le Confort Médical SA (BLC) | $35.71 Million | 16.49% | 1.06x | $177.62 Million |
| Metrics in Balance NV (MLMIB) | $-170.25K | 0.00% | 0.00x | $144.89K |
About Euromedis Groupe SA
Laboratoires Euromedis Société anonyme manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, microperfusionists; infusion and transfusion services, catheters, a… Read more